3437-33-0

Basic information

• Product Name: 3-AZEPAN-1-YL-PROPYLAMINE
• Synonyms: RARECHEM AL BW 2442;AKOS MSC-0395;3-AZEPAN-1-YLPROPAN-1-AMINE;3-AZEPAN-1-YL-PROPYLAMINE;3-HEXAMETHYLENEIMINO-1-PROPYLA MINE;3-(1-AZEPANYL)-1-PROPANAMINE;ASINEX-REAG BAS 04085419;(3-azepan-1-ylpropyl)amine(SALTDATA: FREE)
• CAS NO: 3437-33-0
• Molecular Formula: C₉H₂₀N₂
• Molecular Weight: 156.27
• Mol File: 3437-33-0.mol

Chemical Properties

• Boiling Point: 70-72°C 0,5mm
• Flash Point: 85.4°C
• Appearance: /
• Density: 0.9g/cm³
• Vapor Pressure: 0.0625mmHg at 25°C
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 3-AZEPAN-1-YL-PROPYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AZEPAN-1-YL-PROPYLAMINE(3437-33-0)
• EPA Substance Registry System: 3-AZEPAN-1-YL-PROPYLAMINE(3437-33-0)

Safety Data

• Hazard Codes: Xi
• Statements: 34
• Safety Statements: 26-36/37/39
• RIDADR: 2735
• HazardClass: IRRITANT
• Hazardous Substances Data: 3437-33-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-AZEPAN-1-YL-PROPYLAMINE is used as a structural lead for the refinement of centrally acting oxime reactivators of phosphylated cholinesterases. These reactivators are essential in the treatment of conditions caused by the inhibition of cholinesterase enzymes, such as those resulting from exposure to nerve agents or certain pesticides. 3-AZEPAN-1-YL-PROPYLAMINE's unique structure allows for the development of more effective and targeted therapies, potentially improving patient outcomes and reducing side effects.

InChI:InChI=1/C9H20N2/c10-6-5-9-11-7-3-1-2-4-8-11/h1-10H2/p+2

Upstream product

• 937-51-9 3-(Perhydroazepin-1-yl)propionitril 
• 1201218-91-8 2-(3-(azepan-1-yl)propyl)isoindoline-1,3-dione 
• 111-49-9 hexamethylene imine 
• 24566-95-8 1-(3-aminopropyl)hexahydro-1H-azepin-2-one 

Downstream Products

• 110045-57-3 N-[4-(3-Azepan-1-yl-propylamino)-6-trichloromethyl-[1,3,5]triazin-2-yl]-N'-(4-chloro-phenyl)-guanidine 
• 901716-44-7 N-(3-(azepan-1-yl)propyl)-1-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methyl)piperidine-4-carboxamide 
• 1201219-08-0 perfluorophenyl 4-(4-(4-(5-(3-(azepan-1-yl)propylcarbamoyl)-1-methyl-1H-pyrrol-3-ylcarbamoyl)benzoyl)benzamido)-1-methyl-1H-pyrrole-2-carboxylate 
• 123777-58-2 2,5-bis-(3-hexahydroazepin-1-yl-propylamino)-[1,4]benzoquinone 
• 1221182-71-3 3-(azepan-1-yl)-N-benzyl-N-methylpropan-1-amine 

Relevant articles and documents

Identification and Structure–Activity Relationship Studies of Small-Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1

The methyllysine reader protein Spindlin1 has been implicated in the tumorigenesis of several types of cancer and may be an attractive novel therapeutic target. Small-molecule inhibitors of Spindlin1 should be valuable as chemical probes as well as potential new therapeutics. We applied an iterative virtual screening campaign, encompassing structure- and ligand-based approaches, to identify potential Spindlin1 inhibitors from databases of commercially available compounds. Our in silico studies coupled with in vitro testing were successful in identifying novel Spindlin1 inhibitors. Several 4-aminoquinazoline and quinazolinethione derivatives were among the active hit compounds, which indicated that these scaffolds represent promising lead structures for the development of Spindlin1 inhibitors. Subsequent lead optimization studies were hence carried out, and numerous derivatives of both lead scaffolds were synthesized. This resulted in the discovery of novel inhibitors of Spindlin1 and helped explore the structure–activity relationships of these inhibitor series.

COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDERS, PAIN AND OTHER DISEASES

The present invention provides compounds which antagonize epsilon protein kinase C (PKCε). These compounds have a structural formula (Ia), (Ic) or (II). The present invention also provides pharmaceutical compositions containing these compounds and methods of treating various diseases, conditions, and/or symptoms by using these compounds.

Solution-phase parallel synthesis of novel membrane-targeted antibiotics

The increase in the incidence of antibiotic-resistant infections is a major concern to healthcare workers and requires the development of novel antibacterial agents. Recently, we described a series of benzophenonecontaining antibiotics which displayed activity against antibiotic-resistant bacteria. We have shown that these agents function by disrupting the bacterial membrane. To further explore these compounds, a practical and efficient solution-phase parallel synthesis method was developed which allowed us to prepare combinatorial libraries of these agents. Using this method, we prepared 218 compounds in 58 reactions. All of the compounds were characterized by HPLC and MALDI-TOF mass spectrometry. Analysis of this library for antibacterial activity identified six compounds which displayed MTC values of 2.0 mg/T. against Staphylococcus aureus. Examination of the structure-function relationships of these agents revealed that cationic groups were required and that cyclic, aliphatic amines were crucial for activity. Using the information generated here, we speculate on how the various structural features of the molecule are necessary for the interaction with the bacterial membrane.